[go: up one dir, main page]

MX2016004678A - Composiciones para el tratamiento del cancer. - Google Patents

Composiciones para el tratamiento del cancer.

Info

Publication number
MX2016004678A
MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating cancer
treatment
cancer
Prior art date
Application number
MX2016004678A
Other languages
English (en)
Inventor
A Toretsky Jeffrey
Uren Aykut
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of MX2016004678A publication Critical patent/MX2016004678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y composiciones aquí proporcionadas se relacionan con el tratamiento del cáncer. En algunas modalidades, las composiciones titnen utilizad en el tratamiento de cánceres incluyendo glibastoma multiforme y cáncer de pulmón.
MX2016004678A 2013-10-24 2014-10-20 Composiciones para el tratamiento del cancer. MX2016004678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2016004678A true MX2016004678A (es) 2017-03-10

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004678A MX2016004678A (es) 2013-10-24 2014-10-20 Composiciones para el tratamiento del cancer.

Country Status (11)

Country Link
US (2) US9511050B2 (es)
EP (1) EP3060207A4 (es)
JP (1) JP6389884B2 (es)
KR (1) KR20160065986A (es)
CN (1) CN105848654B (es)
AU (1) AU2014340398A1 (es)
CA (1) CA2927148A1 (es)
IL (1) IL245281A0 (es)
MX (1) MX2016004678A (es)
RU (1) RU2016114498A (es)
WO (1) WO2015061229A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
SG10201900514RA (en) 2008-10-22 2019-02-27 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
KR102145835B1 (ko) 2012-04-12 2020-08-20 조지타운 유니버시티 유잉육종계 종양을 치료하기 위한 조성물
CA2927148A1 (en) * 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
EA032644B1 (ru) 2014-10-09 2019-06-28 Онктернал Терапьютикс, Инк. Производные индолинона и их применение
EP3699181B1 (en) 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR20180102544A (ko) 2015-10-26 2018-09-17 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법
DK3436434T3 (da) 2016-03-31 2020-09-21 Oncternal Therapeutics Inc Indolin-analoger og anvendelser deraf
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
KR20210095721A (ko) 2016-07-29 2021-08-02 온크터널 테라퓨틱스, 인코포레이티드. 인돌리논 화합물의 용도
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
KR102747156B1 (ko) * 2017-02-28 2024-12-26 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 전립선 암의 검출
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
JP2002531498A (ja) * 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル活性剤としてのイサチン誘導体の使用方法
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008083326A2 (en) 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
WO2008130669A1 (en) 2007-04-20 2008-10-30 The Research Foundation Of State University Of New York Benzimidazoles and pharmaceutical compositions thereof
WO2013151981A1 (en) * 2012-04-02 2013-10-10 Gradalis, Inc. Ewing's sarcoma bifunctional shrna design
KR102145835B1 (ko) 2012-04-12 2020-08-20 조지타운 유니버시티 유잉육종계 종양을 치료하기 위한 조성물
CA2927148A1 (en) * 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer

Also Published As

Publication number Publication date
CA2927148A1 (en) 2015-04-30
CN105848654A (zh) 2016-08-10
CN105848654B (zh) 2018-10-02
RU2016114498A (ru) 2017-11-29
RU2016114498A3 (es) 2018-08-13
US20170157089A1 (en) 2017-06-08
KR20160065986A (ko) 2016-06-09
EP3060207A1 (en) 2016-08-31
AU2014340398A1 (en) 2016-06-09
JP6389884B2 (ja) 2018-09-12
US9511050B2 (en) 2016-12-06
WO2015061229A1 (en) 2015-04-30
IL245281A0 (en) 2016-06-30
JP2016534084A (ja) 2016-11-04
US20160263086A1 (en) 2016-09-15
EP3060207A4 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
MX2016004678A (es) Composiciones para el tratamiento del cancer.
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016002974A (es) Eteres de arilo y sus usos.
SG11201510751YA (en) Composition and vaccine for treating prostate cancer
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
TW201611843A (en) Methods of treatment with arginine deiminase
GEP20197049B (en) Compositions and methods for treating surface wounds
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IN2014DN09228A (es)
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
NZ628433A (en) Chitosan-derived compositions
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA032501B9 (ru) Способы и композиции для содействия заживлению острой раны и хронической раны
MX2015013021A (es) 5-bromo-indirrubinas.